Influence of autonomic neuropathy, systemic inflammation and other clinical parameters on mortality in dialysis patients.

Abstract

Background: Autonomic neuropathy (AN) is prevalent in diabetes and chronic kidney disease. The Composite Autonomic Symptom Score 31 (COMPASS 31) is a self-assessment test developed to determine not only cardiac AN but also AN of other organs, including the vasomotor, pupillomotor, secretomotor, and gastrointestinal systems. As yet there are no data on the effects of combined AN-scores of a variety of affected organ systems on mortality in dialysis patients.

Methods: In 119 patients undergoing hemodialysis therapy, symptoms of AN were documented using COMPASS 31. After 5 years, survival rates were calculated depending on AN scores and other parameters. After this 5-year period, AN scores were assessed for a second time and correlated with those obtained 5 years earlier.

Results: Survival rates for patients with lower AN scores were better than for those with higher AN scores. Patients with lower C-reactive protein levels showed better survival compared to those with higher values. Dialysis patients with diabetes had a lower survival rate compared to non-diabetic patients. In women, survival rates were better than in men. AN scores remained unchanged over the 5-year period.

Conclusion: AN is frequently observed in dialysis patients and can be identified through the COMPASS 31 questionnaire. Patients with higher AN scores exhibit poorer survival rates compared to those with lower scores. This observation is applicable not only for cardiac AN but also to AN scores reflecting changes in other organ systems. Therefore, AN scores can be used effectively to detect various AN symptoms in dialysis patients and identify their increased risk of mortality.